Bioinformatics of Brain Diseases

217

[36] K. G. Becker, K. C. Barnes, T. J. Bright, et al., “The genetic association

database,” Nature Genetics, vol. 36, pp. 431–432, 2004.

[37] J. S. Amberger, C. A. Bocchini, A. F. Scott, et al., “Omim.org: lever-

aging knowledge across phenotype–gene relationships,” Nucleic Acids

Research, vol. 47, pp. D1038–D1043, 2018.

[38] A. Bauer-Mehren, M. Bundschus, M. Rautschka, et al., “Gene-disease

network analysis reveals functional modules in mendelian, complex and

environmental diseases,” PLoS ONE, vol. 6, 2011.

[39] N. Grech, T. A. Dalli, S. Mizzi, et al., “Rising incidence of glioblastoma

multiforme in a well-defined population,” Cureus, vol. 12, 2020.

[40] K. M. Bhawe and M. K. Aghi, “Microarray analysis in glioblastomas,”

Methods in molecular biology, vol. 1375, pp. 195–206, 2016.

[41] S. Wang, F. Liu, Y. Wang, et al., “Integrated analysis of 34 microar-

ray datasets reveals cbx3 as a diagnostic and prognostic biomarker in

glioblastoma,” Journal of Translational Medicine, vol. 17, 2019.

[42] Y. Zhang, J. Xu, and X. Zhu, “A 63 signature genes prediction system is

effective for glioblastoma prognosis,” International Journal of Molecular

Medicine, vol. 41, pp. 2070–2078, 2018.

[43] M. A. Wedemeyer, I. S. Muskens, B. A. Strickland, et al., “Epigenetic

dysregulation in meningiomas,” Neuro-Oncology Advances, vol. 4, 2022.

[44] F. Menghi, F. Orzan, M. Eoli, et al., “Dna microarray analysis identi-

fies cks2 and lepr as potential markers of meningioma recurrence,” The

oncologist, vol. 16 10, pp. 1440–50, 2011.

[45] D. Villa, K. L. Tan, C. Steidl, et al., “Molecular features of a large cohort

of primary central nervous system lymphoma using tissue microarray,”

Blood advances, vol. 3 23, pp. 3953–3961, 2019.

[46] Y. Takashima, A. Kawaguchi, Y. Iwadate, et al., “mir-101, mir-548b,

mir-554, and mir-1202 are reliable prognosis predictors of the mirnas

associated with cancer immunity in primary central nervous system lym-

phoma,” PLoS ONE, vol. 15, 2020.

[47] H. Takei, L. W. Buckleair, A. L. Rivera, et al., “Brain tissue microarrays

in neurodegenerative diseases: Validation of methodology and immuno-

histochemical study of growth‐associated protein‐43 and calretinin,”

Pathology International, vol. 57, 2007.

[48] C. Blauwendraat, O. Pletnikova, J. T. Geiger, et al., “Genetic analysis

of neurodegenerative diseases in a pathology cohort,” Neurobiology of

Aging, vol. 76, pp. 214.e1–214.e9, 2019.